Domov › Rakovina gastrointestinálneho traktu › Massachusetts
Klinické štúdie Rakovina gastrointestinálneho traktu v štáte Massachusetts
15 štúdií pre Rakovina gastrointestinálneho traktu hľadá účastníkov v zariadeniach v štáte Massachusetts.
Mestá v štáte Massachusetts
Oficiálny text štúdie (anglicky)
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Dana-Farber Cancer Institute - Oncology Department, Boston
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT06760819Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Brigham and Women's Hospital (BWH), Boston
- Dana-Farber Cancer Institute (DFCI), Boston
- Dana-Farber Brigham Cancer Center - Foxborough, Foxborough
- a 2 ďalších
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT07222800A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
- GSK Investigational Site, Boston
- GSK Investigational Site, Boston
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT07218926Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Dana Farber Cancer Institute, Boston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT06128551Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT06445062SURGE: Supporting Utility and Representation in Genomics-based Cancer Trial Enrollment (Intervention)
- Dana Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute at St. Elizabeth's Medical Center, Brighton
- Dana-Farber Cancer Instiute - Merrimack Valley, Methuen
Prebieha nábor
Vek 18 a viac · Všetky pohlavia · Aktualizované 16. 9. 2026 · NCT05375643Resilience and Equity in Aging, Cancer, and Health (REACH)
- Dana-Farber Cancer Institute, Boston
Prebieha nábor
Vek 65 a viac · Všetky pohlavia · Aktualizované 10. 9. 2026 · NCT04674267Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 9. 9. 2026 · NCT04899908A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
- Dana-Farber Cancer Institute, Boston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 27. 8. 2026 · NCT07544589A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Massachusetts General Hospital Cancer Center, Boston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 11. 8. 2026 · NCT05592626BOLSTER: Learning New Skills to Thrive
- Dana-Farber Cancer Institute, Boston
Prebieha nábor
Vek 18 a viac · Všetky pohlavia · Aktualizované 18. 6. 2026 · NCT06936878Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 3. 6. 2026 · NCT06040541A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Massachusetts General Hospital,, Boston
Prebieha náborFáza 1/2
Vek 12 a viac · Všetky pohlavia · Aktualizované 27. 5. 2026 · NCT03093116Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Dana Farber Cancer Institute, Boston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 15. 5. 2026 · NCT05379985A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Massachusetts General Hospital, Boston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 4. 2026 · NCT07020221Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.